echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Non-alcoholic fatty liver disease and hepatocellular carcinoma: the time has come to bridge the gap

    Non-alcoholic fatty liver disease and hepatocellular carcinoma: the time has come to bridge the gap

    • Last Update: 2021-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease, affecting more than 25% of the global population


    In this issue of "Hepatology", Simon and his colleagues reported data from a large group of people to fill this critical gap


    Cirrhosis of the liver is the main risk factor for hepatocellular carcinoma.


    Collaboration is currently underway to provide practical guidance on various aspects of care from screening and diagnosis to treatment of non-alcoholic fatty liver patients


    references

    George Cholankeril et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.